FDA Reviewers Set High Efficacy Bar for Sanofi’s Lemtrada in MS

Drug Industry Daily
A A
Sanofi’s bid to expand the indication for its biologic Lemtrada to treat relapsing multiple sclerosis (MS) faces tough scrutiny by FDA advisors as agency reviewers say data supporting the application point to “serious and potentially fatal safety issues.”

To View This Article:

Login

Subscribe To Drug Industry Daily